lenalidomide – Medxy AI

Novel Efficacy and Safety of Obinutuzumab Combined with Lenalidomide in First-Line Treatment of High Tumor Burden Follicular Lymphoma

By MedXY 08/30/2025

This phase 2 study demonstrates that obinutuzumab plus lenalidomide achieves high response rates with durable progression-free survival and manageable toxicities in untreated high tumor burden follicular lymphoma, suggesting a promising frontline option.

Clinical Updates Wellness & Lifestyle

Optimizing Therapy in Transplant-Ineligible Multiple Myeloma: Insights from the REST Phase 2 Trial on Isatuximab, Bortezomib, Lenalidomide, and Limited Dexamethasone

By MedXY 08/30/2025

The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.

Clinical Updates Wellness & Lifestyle

Carfilzomib-Lenalidomide-Dexamethasone in Transplant-Ineligible Multiple Myeloma: High MRD Negativity and PFS Benefit in the EMN20 Trial

By MedXY 08/07/2025

The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxicity.